# Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

> **NCT05248373** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 400 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** Gam-COVID-Vac
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05248373
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-08
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-12-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248373, "Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05248373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*